Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 16, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Sparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis...
-
Aug 31, 2021
2021 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) includes new recommendations on management of iron deficiency with Ferinject® (ferric carboxymaltose)...
-
Aug 24, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing...
-
Aug 5, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Net sales up 5.0% and EBITDA up 5.3% at constant exchange rates (CER), as patient access recovered in line with easing COVID-19 restrictions in key...
-
Jun 24, 2021
COVID-19 pandemic significantly impacted the DIAMOND study, leading to lower-than-anticipated enrolment and slower incidence of cardio-vascular events Independent study Executive Committee...